Tema Heart & Health ETF
Tema Heart & Health ETF reported 46 holdings worth US$51.9M as of May 31, 2026 (Form N-PORT)
As of May 31, 2026 · Filed Jul 29, 2026
Tema Heart & Health ETF reported 46 holdings worth US$51.9M as of May 31, 2026. Largest: Eli Lilly And Company, Unitedhealth Group Incorporated and Novo Nordisk A/s Class B. Filed Jul 29, 2026 (Form N-PORT).
- Holdings
- 46
- Value as reported
- US$51.9M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 5,413 | US$5.98M | 11.5% |
| Unitedhealth Group Incorporated | 7,159 | US$2.72M | 5.2% |
| Novo Nordisk A/s Class B | 59,455 | US$2.72M | 5.2% |
| Roche Holding Ltd | 5,436 | US$2.33M | 4.5% |
| Merck & Company, Inc. | 18,672 | US$2.22M | 4.3% |
| Astrazeneca Plc | 11,178 | US$2.08M | 4.0% |
| Thermo Fisher Scientific Inc | 4,185 | US$2.06M | 4.0% |
| Johnson & Johnson | 8,274 | US$1.86M | 3.6% |
| Gilead Sciences, Inc. | 13,261 | US$1.78M | 3.4% |
| Novartis Ag | 11,627 | US$1.76M | 3.4% |
| Revolution Medicines, Inc. | 10,971 | US$1.73M | 3.3% |
| Vertex Pharmaceuticals Incorporated | 3,398 | US$1.52M | 2.9% |
| Danaher Corporation | 7,557 | US$1.38M | 2.7% |
| Abbott Laboratories | 15,809 | US$1.35M | 2.6% |
| Bridgebio Pharma, Inc. | 20,327 | US$1.35M | 2.6% |
| Cytokinetics, Incorporated | 17,069 | US$1.31M | 2.5% |
| Abbvie Inc. | 5,714 | US$1.24M | 2.4% |
| Bristol-myers Squibb Company | 18,939 | US$1.08M | 2.1% |
| Teva Pharmaceutical Industries Limited | 30,273 | US$1.07M | 2.1% |
| Dexcom, Inc. | 13,512 | US$996K | 1.9% |
| Amgen Inc. | 2,946 | US$992K | 1.9% |
| Medtronic Plc. | 13,203 | US$975K | 1.9% |
| Edwards Lifesciences Corporation | 10,488 | US$907K | 1.7% |
| Mckesson Corporation | 1,196 | US$888K | 1.7% |
| Regeneron Pharmaceuticals, Inc. | 1,408 | US$866K | 1.7% |
| Madrigal Pharmaceuticals, Inc. | 1,519 | US$755K | 1.5% |
| Boston Scientific Corporation | 15,285 | US$738K | 1.4% |
| Chugai Pharmaceutical Co., Ltd. | 13,915 | US$690K | 1.3% |
| Intuitive Surgical, Inc. | 1,590 | US$675K | 1.3% |
| Alnylam Pharmaceuticals, Inc. | 1,954 | US$590K | 1.1% |
| Arrowhead Pharmaceuticals, Inc. | 7,240 | US$564K | 1.1% |
| Scholar Rock Holding Corporation | 9,647 | US$476K | 0.92% |
| Xenon Pharmaceuticals Inc. | 8,393 | US$459K | 0.88% |
| Ionis Pharmaceuticals, Inc. | 5,599 | US$428K | 0.83% |
| Insulet Corporation | 2,835 | US$411K | 0.79% |
| Ascendis Pharma A/s | 1,755 | US$393K | 0.76% |
| Insmed Incorporated | 3,449 | US$369K | 0.71% |
| Stoke Therapeutics, Inc. | 10,049 | US$311K | 0.60% |
| Viking Therapeutics, Inc. | 8,538 | US$280K | 0.54% |
| Mbx Biosciences, Inc. | 8,761 | US$276K | 0.53% |
| Zealand Pharma A/s | 5,293 | US$268K | 0.52% |
| Gubra A/s | 4,487 | US$250K | 0.48% |
| Intellia Therapeutics, Inc. | 13,892 | US$195K | 0.38% |
| Crinetics Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Masimo Corporation | 0 | US$0 | 0.00% |
| Neurocrine Biosciences, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related